Drug Makers Buy Doctors
The story of how pharmaceutical firms buy doctors to prescribe given medication would be unbelievable if it appeared in some publication with less credibility than the Bulletin of the AARP.
Here’s the reported way in which a sales manager at Astra-Zeneca described the filthy operation: “There’s a big bucket of money sitting in every office. Every time you go in you reach your hand in the bucket and grab a handful.”
Little did the teller of this tale expect that his words would turn up on the Internet. But they did.
But even if they did not, the truth about the way in which pharmaceutical firms seek to buy doctors to prescribe their product would have been brought to public attention. A two-year Senate Finance Committee probe has concluded that by funding continuing medical education programs for doctors, pharmaceutical companies “have been able to increase their market for new products” and to illegally promote “off label uses” for their drugs. The committee has expressed concern that persuading doctors to use more costly drugs raises safety issues and most certainly places an additional cost on government funding.
The New England Journal of Medicine reports that 94% of doctors have a relationship with drug companies, 83% get free meals and 35% attend industry events.
They used to call such acts “bribery.” Now, we guess it goes under another name — like friendship.
A message from our CEO & publisher Rachel Fishman Feddersen
I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.
At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and polarized discourse.
Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.
— Rachel Fishman Feddersen, Publisher and CEO